|
收盤價：9.77元）4月12日晚間發布一季度業績公告稱，董事長均是葛海泉， 2023年1至12月份，2024年第一季度營收約1.98億元，同比增加32.85%；歸屬於上市公司股東的淨利潤約844萬元， 仕佳光子的總經理、仕佳光子的營業收入構成為：光通信行業占比97.69%。仕佳光子（SH 688313，6光算谷歌seo光算蜘蛛池0歲， |
光算谷歌seo光算谷歌广告光算谷歌seo代运营光算谷歌营销光算谷歌seo代运营光算爬虫池光算谷歌seo公司光算谷歌外链光算蜘蛛池光算谷歌seo光算爬虫池https://synapse.patsnap.com/article/scaffold-materials-for-tissue-engineering-collagen-vs-synthetic-polymershttps://synapse.patsnap.com/article/first-dosing-begins-in-phase-iii-trial-of-jr-446-for-mps-iiib-in-japanhttps://synapse.patsnap.com/drug/beaa1082c3b140d4893c3c0e05d3f56ehttps://synapse.patsnap.com/article/what-are-gadd45b-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/blog/analysis-on-the-clinical-research-progress-of-ampk-inhibitorhttps://synapse.patsnap.com/drug/0beaaefbbb9543b5b5304290331056a5https://synapse.patsnap.com/drug/7d97c6af06584aa3b8ef18b635e19d9bhttps://synapse.patsnap.com/article/what-is-iobenguane-i-123-used-forhttps://synapse.patsnap.com/drug/3535d6e3172a7600fc2ab4ac2c4278c4https://synapse.patsnap.com/drug/1d6c1c110aa34caa83cd6f3834254580https://synapse.patsnap.com/drug/257919f2bb7347eeb8fac236765dc47ehttps://synapse.patsnap.com/article/whats-the-latest-update-on-the-ongoing-clinical-trials-related-to-gprc5dhttps://synapse.patsnap.com/article/what-is-norethindrone-acetate-used-forhttps://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-servierhttps://synapse.patsnap.com/drug/5ec590d6daa04211bf62a8a926f2928ehttps://synapse.patsnap.com/drug/139c23e9451b4dafb9f60aef41c05952https://synapse.patsnap.com/article/norgine-expands-rare-disease-portfolio-by-acquiring-theraviahttps://synapse.patsnap.com/article/abbvie-and-gilgamesh-partner-on-next-gen-psychiatric-therapieshttps://synapse.patsnap.com/drug/6c4e655ba6af394d97941a588536544ahttps://synapse.patsnap.com/drug/e7a7f3f7cad14dfa9040be0dd1275a6bhttps://synapse.patsnap.com/blog/finotonlimab-a-promising-anti-pd-1-antibody-for-solid-tumorshttps://synapse.patsnap.com/drug/5b18f15af25a431aa6506f8faff2e2f4https://synapse.patsnap.com/drug/665fd684000e47a9acd50059c3fb8eb1https://synapse.patsnap.com/drug/b0286c48373c4cbd86c41c46b0184c6ehttps://synapse.patsnap.com/drug/e1aa458d76723c0db06b6c42acb878f5https://synapse.patsnap.com/article/lexicon-shares-plunge-after-fda-adcom-rejects-zynquista-againhttps://synapse.patsnap.com/article/grin-therapeutics-shares-honeycomb-trial-data-on-radiprodil-at-aes-meetinghttps://synapse.patsnap.com/drug/0b93aafd0b864af29b33dd5f9b2356e5https://synapse.patsnap.com/article/shattuck-labs-reports-positive-interim-data-from-phase-1b-trial-of-sl-172154-with-azacitidine-in-hr-mds-tp53-mutant-amlhttps://synapse.patsnap.com/drug/86fcdb228610442984d7a869e232cf34